{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:53:02Z","timestamp":1781826782483,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012416","name":"Bundesministerium f\u00fcr Digitalisierung und Wirtschaftsstandort","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010132","name":"\u00d6sterreichische Nationalstiftung f\u00fcr Forschung, Technologie und Entwicklung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006012","name":"Christian Doppler Forschungsgesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clon.2026.104169","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:11:42Z","timestamp":1776575502000},"page":"104169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Trastuzumab in Addition to Chemotherapy in Patients With Metastatic Human Epidermal Growth Factor Receptor 2\u2013Positive Gastroesophageal Cancer\u2014A Real-World Experience"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8508-1640","authenticated-orcid":false,"given":"M.","family":"Korpan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Simonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Soellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"Edelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.J.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pellizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.V.","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1695-8577","authenticated-orcid":false,"given":"J.M.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7854-7781","authenticated-orcid":false,"given":"G.W.","family":"Prager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0374-1408","authenticated-orcid":false,"given":"E.S.","family":"Bergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-6797","authenticated-orcid":false,"given":"A.S.","family":"Berghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"M.","family":"Preusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-0873","authenticated-orcid":false,"given":"A.","family":"Ilhan-Mutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7203-8732","authenticated-orcid":false,"given":"H.C.","family":"Puhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2026.104169_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J Clinicians"},{"key":"10.1016\/j.clon.2026.104169_bib2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/cancers17030340","article-title":"Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns","volume":"17","author":"Korpan","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.clon.2026.104169_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2026.104169_bib4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2026.104169_bib5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.clon.2026.104169_bib6","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clon.2026.104169_bib7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2026.104169_bib8","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1016\/j.annonc.2022.04.249","article-title":"P-159 Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-Gastric04): A randomized phase 3 study","volume":"33","author":"Shitara","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2026.104169_bib9","doi-asserted-by":"crossref","first-page":"S1542","DOI":"10.1016\/j.annonc.2023.10.307","volume":"34","author":"Shen","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2026.104169_bib10","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2026.104169_bib11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","article-title":"Adjusting for multiple testing--when and how?","volume":"54","author":"Bender","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clon.2026.104169_bib12","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","article-title":"Real-World Evidence in Oncology: Opportunities and Limitations","volume":"25","author":"Di Maio","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.clon.2026.104169_bib13","doi-asserted-by":"crossref","first-page":"e1181","DOI":"10.1634\/theoncologist.2020-0109","article-title":"Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction","volume":"25","author":"Al-Batran","year":"2020","journal-title":"The Oncologist"},{"key":"10.1016\/j.clon.2026.104169_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12885-021-08058-2","article-title":"Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data","volume":"21","author":"Kim","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2026.104169_bib15","doi-asserted-by":"crossref","first-page":"113370","DOI":"10.1016\/j.ejca.2023.113370","article-title":"Treatment of gastric adenocarcinoma: A rapidly evolving landscape","volume":"195","author":"Taieb","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2026.104169_bib16","first-page":"CD005048","article-title":"Interventions for dysphagia in oesophageal cancer","volume":"2014","author":"Dai","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clon.2026.104169_bib17","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO.20.01254","article-title":"Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial","volume":"39","author":"Lu","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.clon.2026.104169_bib18","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/annonc\/mds640","article-title":"The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study","volume":"24","author":"Prins","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2026.104169_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12885-018-5242-4","article-title":"HER2\/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma","volume":"19","author":"Plum","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2026.104169_bib20","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00432-014-1900-3","article-title":"HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison","volume":"141","author":"Koopman","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clon.2026.104169_bib21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1470-2045(20)30169-8","article-title":"First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial","volume":"21","author":"Janjigian","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2026.104169_bib22","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.2217\/fon-2022-0595","article-title":"HERIZON-GEA-01: Zanidatamab + chemo \u00b1 tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma","volume":"18","author":"Tabernero","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.clon.2026.104169_bib23","doi-asserted-by":"crossref","first-page":"TPS424","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS424","article-title":"Phase 1b\/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03)","volume":"42","author":"Janjigian","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.clon.2026.104169_bib24","doi-asserted-by":"crossref","first-page":"S1123","DOI":"10.1016\/j.annonc.2022.07.1378","article-title":"1260TiP The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: A randomized multi-center study in resectable HER2 overexpressing adenocarcinoma of the esophagus or gastroesophageal junction (TRAP-2)","volume":"33","author":"Blang\u00e9","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2026.104169_bib25","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1200\/JCO.20.02761","article-title":"HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study","volume":"39","author":"Haffner","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2026.104169_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.21873\/anticanres.13927","article-title":"Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer","volume":"40","author":"Kijima","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clon.2026.104169_bib27","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.clon.2026.104169_bib28","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00428-019-02541-9","article-title":"HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany","volume":"474","author":"Baretton","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clon.2026.104169_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000519602","article-title":"Epidemiological Review of Gastroesophageal Junction Adenocarcinoma in Asian Countries","volume":"103","author":"Manabe","year":"2021","journal-title":"Digestion"},{"key":"10.1016\/j.clon.2026.104169_bib30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1470-2045(21)00718-X","article-title":"Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology\/RTOG 1010): a multicentre, randomised, phase 3 trial","volume":"23","author":"Safran","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2026.104169_bib31","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1093\/annonc\/mds104","article-title":"Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis","volume":"23","author":"Janjigian","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526001408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526001408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:24:09Z","timestamp":1781825049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526001408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"alternative-id":["S0936655526001408"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104169","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trastuzumab in Addition to Chemotherapy in Patients With Metastatic Human Epidermal Growth Factor Receptor 2\u2013Positive Gastroesophageal Cancer\u2014A Real-World Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"104169"}}